Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

GE Healthcare Life Sciences Launches Xuri™ Technology Family

Published: Wednesday, November 13, 2013
Last Updated: Wednesday, November 13, 2013
Bookmark and Share
First product introduced - Xuri Cell Expansion System W25 for the clinical manufacture of cellular immunotherapies.

GE Healthcare Life Sciences has launched Xuri™, a new technology family designed specifically to support and advance the field of cell therapy.

The new technology family, in which the first product is the Xuri Cell Expansion System W25 for the manufacture of cellular immunotherapies in a clinical setting, will combine GE Healthcare’s capabilities in cellular science with the company’s expertise in the development of advanced tools for the manufacture of biopharmaceuticals.

Cell therapy and regenerative medicine, the use of cells to replace damaged tissue or to treat disease, shows great promise for treating many life-threatening and life-limiting illnesses such as cancer, heart disease, Parkinson’s and age-related macular degeneration.

The widespread adoption of these therapies will require the development of robust, scalable manufacturing tools and workflows to generate sufficient, high quality cells for infusion into patients.

With an estimated 2,500 on-going cell therapy and regenerative medicine clinical trials worldwide, many research groups are now looking at how to move from small-scale expansion of cells to a cost-effective, industrialized process.

GE Healthcare’s new Xuri Cell Expansion System W25 is a functionally closed, automated system, specifically designed to be suitable for the requirements of scaling-out cell therapies in a clinical setting.

The system is equipped with dedicated software applications to make it suitable for a regulated manufacturing environment and has been validated for T-cell growth.

The Xuri W25 builds on the GE Healthcare’s WAVE Bioreactor™ technology which is widely used in the development and manufacture of biopharmaceuticals globally.

Eric Roman, General Manager of Research & Applied Markets, GE Healthcare Life Sciences, commented, “Through our scale and innovation, we are committed to addressing the significant challenges that remain in moving from highly promising experimental cell therapies to widely available and affordable treatments. We have an extensive research program, working with leaders in the field such as the Karolinska University Hospital, to develop tailored technologies and workflows. The focus of our Xuri technology family is to enable the safe, reliable and efficient progress of cell therapies from clinical development to commercialization.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GE Healthcare Life Sciences Strengthens Business Resilience with ISO 22301
$100 million investment to double manufacturing capacity for chromatography media by 2018.
Saturday, December 05, 2015
GE Healthcare Life Sciences and Emerson Team Up
Collaboration will help drive improvements in productivity.
Saturday, November 28, 2015
GE Healthcare Life Sciences to Open Biopharmaceutical Technology and Training Laboratory in Turkey
Supports Turkey’s ambitions to expand domestic biopharmaceutical industry. Laboratory will be a key component of GE’s new Innovation Center in Istanbul.
Friday, November 14, 2014
GE Healthcare Life Sciences Named as Finalist for Four Bioprocess Industry Awards
Awards celebrate and recognize the outstanding people, organizations and technologies.
Saturday, October 04, 2014
GE Healthcare Life Sciences to Create New US Headquarters
When fully operational, the new facility will house more than 500 highly skilled employees and bring more than 220 new jobs to Massachusetts.
Wednesday, August 20, 2014
GE Healthcare Appoints Emmanuel Ligner as General Manager
Emmanuel will oversee all worldwide commercial activities of Company's rapidly growing BioProcess business.
Friday, April 11, 2014
GE Healthcare to Build KUBio Factory for JHL Biotech in China
New factory to give JHL Biotech commercial biopharmaceutical manufacturing capabilities in Asia.
Thursday, September 26, 2013
GE Healthcare Life Sciences and Osaka University Team Up
Top four graduate students to be hosted at GE Healthcare Life Science’s Uppsala site.
Wednesday, August 21, 2013
GE Healthcare Life Sciences Completes Acquisition of Xcellerex, Inc.
Acquisition expands GE Healthcare’s offering of technologies and services for the manufacture of recombinant proteins, antibodies and vaccines.
Tuesday, May 15, 2012
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Eisai Establishes AiM Institute
The Andover innovative Medicines (AiM) Institute will develop innovative precision medicines for hard-to-treat conditions.
Antibodies that Target Holes in HIV's Defence Identified
Scientists suggest 'holes' in HIV sugar sheild can be targeted by antibodies.
Discovery Could Yield Improved Flu Vaccines
Researchers have discovered a type of immune antibody that can evolve to combat a number of infuenza virus strains.
First Accurate Simulation of a Virus Invading a Cell
For the first time, scientists know what happens to a virus’ shape when it invades a host cell.Understanding how the virus shape specifically changes could lead to more effective anti-viral therapies.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!